成人疫苗接种的成本效果:一项系统综述
该研究系统检索1980至2016年美加成人疫苗接种的经济学评价,最终纳入78篇文献。多数研究显示成人疫苗接种具有良好成本效果,支持改进成人免疫推荐的实施。
要点
- 流感、肺炎球菌、百白破等成人疫苗多数研究显示具成本效果。
- 按年龄接种的流感疫苗中56%结局报告成本节约。
- 多数疫苗每QALY成本低于10万美元的结局比例较高。
核心结论
- 多数已发表研究显示成人疫苗接种具有良好成本效果,支持改进成人免疫推荐实施。
研究设计与样本
- 系统检索PubMed、EMBASE、EconLit和Cochrane Library 1980至2016年文献,纳入针对美国或加拿大≥18岁人群的经济评价或成本效果分析,最终分析78篇出版物。
主要发现
- 最终分析纳入78篇出版物:流感25篇、肺炎球菌18篇、人乳头瘤病毒9篇、带状疱疹7篇、破伤风-白喉-百日咳9篇、乙型肝炎9篇、多疫苗1篇。
- 按年龄接种的结局中,报告成本节约的比例:流感56%、肺炎球菌31%、破伤风-白喉-百日咳23%。
- 按年龄接种且报告每QALY成本的结局中,每QALY成本≤10万美元的比例:流感100%、肺炎球菌100%、人乳头瘤病毒69%、带状疱疹71%、破伤风-白喉-百日咳50%。
临床怎么用
- 可将多数成人疫苗具有良好成本效果的经济学证据用于支持改进成人疫苗接种推荐的实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coverage levels for many recommended adult vaccinations are low. The cost-effectiveness research literature on adult vaccinations has not been synthesized in recent years, which may contribute to low awareness of the value of adult vaccinations and to their under-utilization. We assessed research literature since 1980 to summarize economic evidence for adult vaccinations included on the adult immunization schedule. METHODS: We searched PubMed, EMBASE, EconLit, and Cochrane Library from 1980 to 2016 and identified economic evaluation or cost-effectiveness analysis for vaccinations targeting persons aged ≥18 years in the U.S. or Canada. After excluding records based on title and abstract reviews, the remaining publications had a full-text review from two independent reviewers, who extracted economic values that compared vaccination to "no vaccination" scenarios. RESULTS: The systematic searches yielded 1688 publications. After removing duplicates, off-topic publications, and publications without a "no vaccination" comparison, 78 publications were included in the final analysis (influenza = 25, pneumococcal = 18, human papillomavirus = 9, herpes zoster = 7, tetanus-diphtheria-pertussis = 9, hepatitis B = 9, and multiple vaccines = 1). Among outcomes assessing age-based vaccinations, the percent indicating cost-savings was 56% for influenza, 31% for pneumococcal, and 23% for tetanus-diphtheria-pertussis vaccinations. Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations. CONCLUSIONS: The majority of published studies report favorable cost-effectiveness profiles for adult vaccinations, which supports efforts to improve the implementation of adult vaccination recommendations.
引用
- Leidner AJ, Murthy N, Chesson HW, et al. Cost-effectiveness of adult vaccinations: A systematic review. Vaccine. 2018. PMID: 30527660. doi:10.1016/j.vaccine.2018.11.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。